FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： (註7) (i) 上市發行人已收取其在是次股份發行或庫存股份出售或轉讓應得的全部款項； 公司名稱： 美麗田園醫療健康產業有限公司 呈交日期： 2026年1月12日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 ...

Medical Aesthetics - Jiangsu Chuangjian Medical Technology Co., Ltd. received approval for its cross-linked recombinant collagen implant, marking a significant development in the medical aesthetics market [2][17] - The product is designed for facial dermal tissue filling to correct moderate to severe dynamic wrinkles, making it the fifth recombinant collagen implant approved in China and the first cross-linked version [17] - The recombinant collagen industry is shifting from "single type" to "diverse structure," with companies accelerating competition towards full-scenario applications [18] Cosmetics - Lin Qingxuan, a pioneer in the "oil-based skincare" segment, officially listed on the Hong Kong Stock Exchange, becoming the first high-end domestic skincare brand to go public [3][19] - The company has established a comprehensive supply chain system and a unique OMO (Online-Merge-Offline) channel model, which integrates online and offline sales to enhance customer engagement and drive growth [23][35] - Lin Qingxuan's flagship product, the camellia oil essence, has achieved a leading repurchase rate of 33.5% in the industry, indicating strong customer loyalty [27][46] Investment Recommendations - The company recommends focusing on differentiated upstream medical aesthetics product manufacturers and chain medical institutions, highlighting the potential of Meili Tianyuan Medical Health [4][48] - In the cosmetics sector, the emphasis is on domestic brands that innovate in emotional value and safe ingredients, with key recommendations including Lin Qingxuan and other brands that leverage both online and offline channels [4][47] Market Performance - In December, the beauty and personal care index fell by 1.70%, underperforming the broader market, while the medical aesthetics sector saw notable gains from companies like Meili Tianyuan Medical Health and Jinbo Biological [5][10] - For the full year of 2025, the medical aesthetics sector showed mixed performance, with companies like Sihuan Pharmaceutical and Yonghe Medical leading in growth [10] Financial Highlights - Lin Qingxuan reported a total revenue of 1.05 billion yuan in the first half of 2025, reflecting a year-on-year growth of 98.3%, primarily driven by its camellia oil essence [23][41] - The company's gross margin remains high at 82.4%, with specific product categories like essence oil achieving even higher margins [23][41]

美丽田园医疗健康(02373.HK)1月9日耗资108.1万港元回购4.15万股 美丽田园医疗健康(02373.HK)1月8日 耗资45.4万港元回购1.75万股 格隆汇1月9日丨美丽田园医疗健康(02373.HK)公告，1月9日耗资108.1万港元回购4.15万股。 相关事件 ...

美丽田园医疗健康(02373)发布公告，于2026年1月9日，该公司斥资108.1万港元回购4.15万股。 ...

智通财经APP讯，美丽田园医疗健康(02373)发布公告，于2026年1月9日，该公司斥资108.1万港元回购 4.15万股。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 (註7) 公司名稱： 美麗田園醫療健康產業有限公司 呈交日期： 2026年1月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02373 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行 ...

Core Viewpoint - The acquisition of 100% equity in Shanghai Siyuanli Industrial Co., Ltd. by Meili Tianyuan for 1.25 billion yuan is expected to enhance the group's market position and financial performance, contributing to sustained revenue and profit growth for investors [1][2]. Group 1: Acquisition Details - The acquisition was completed on January 7, 2026, and Siyuanli is now a wholly-owned subsidiary of Meili Tianyuan, with its financial results integrated into the group's consolidated financial statements [1]. - Siyuanli achieved a revenue of 850 million yuan and a net profit of 81 million yuan in 2024, indicating its strong operational performance [2]. - Following the acquisition, the total number of the group's stores has expanded to 734, enhancing its market influence [1]. Group 2: Strategic Synergies - Both Meili Tianyuan and Siyuanli operate in 20 major cities, with over 60% of total revenue coming from first-tier cities like Beijing, Shanghai, Guangzhou, and Shenzhen [2]. - The acquisition will integrate approximately 60,000 direct members from Siyuanli into the group's membership system, resulting in a 44% increase in active membership [2]. Group 3: Future Growth Strategies - The group plans to leverage its experience from the acquisition of the second-largest brand, Nairui, to drive Siyuanli's revenue and efficiency growth through systematic output of medical beauty and sub-health services [3]. - The company aims to implement three major strategies: "super brand," "super chain," and "super digitalization," focusing on personalized customer experiences and operational efficiency [3]. - The introduction of AI capabilities into product innovation is a key aspect of the group's strategy, with plans to launch the "Nairui Intelligent Beauty AI" by 2025 [3].

Core Viewpoint - Dongwu Securities initiates coverage on Meili Tianyuan Medical Health (02373) with a "Buy" rating, highlighting its unique "Double Beauty + Double Health" ecosystem, proven acquisition integration capabilities, and excellent operational efficiency, which are expected to drive significant growth in the industry [1] Group 1: Company Overview - The company, established in 1993, has developed a comprehensive beauty and health management service system that includes traditional beauty, medical beauty, and sub-health assessment and intervention [2] - It operates four major brands: Meili Tianyuan, Beili Shi, Xiuker, and Yanyuan, and has strengthened its market position through acquisitions of Nairui'er and Siyuanli, forming a synergistic ecosystem of "life beauty + medical beauty + traditional health + sub-health medical" [2] Group 2: Financial Performance - The company demonstrates strong growth resilience, with revenue increasing from 1.503 billion in 2020 to 2.572 billion in 2024, representing a compound annual growth rate (CAGR) of 11.3% [3] - In the first half of 2025, revenue accelerated to 1.459 billion, a year-on-year increase of 28.2% [3] - Net profit attributable to shareholders rose from 151 million in 2020 to 228 million in 2024, with a year-on-year growth of 34.9% in the first half of 2025, reaching 156 million [3] - Gross margin improved to 49.33% in the first half of 2025, while net margin optimized to 10.67%, reflecting effective cost control and an increase in high-margin business [3] - The company commits to a dividend payout ratio of no less than 50% of net profit attributable to shareholders over the next three years, indicating strong dividend levels [3] Group 3: Industry Outlook - The traditional beauty, light medical beauty, and sub-health sectors are expected to continue expanding, with projected market sizes of 640.2 billion, 415.7 billion, and 29 billion respectively by 2030 [4] - As young consumers increasingly prioritize standardized services and stable experiences, leading companies are expected to gain significant advantages, leading to higher market concentration [4] - The overlapping consumer base in traditional beauty and light medical beauty allows for effective cross-referrals, enhancing customer conversion rates [4] Group 4: Business Synergy and Growth Strategy - The company's core business model exhibits strong synergy, utilizing its extensive and trusted life beauty services as a front-end traffic source to efficiently convert to high-ticket medical beauty and sub-health services, with a cross-business conversion rate of 28.7% in 2024 [5] - The company employs a strategy of "directly operated stores as benchmarks, franchising for coverage," leading to rapid expansion of its store network, which is expected to reach 554 by the end of 2024 [5] - The company has a robust target selection system and post-acquisition digital integration capabilities, as evidenced by the significant improvement in net margin following the acquisition of Nairui'er, showcasing its strong integration and empowerment capabilities [5]

Core Viewpoint - Dongwu Securities initiates coverage on Meili Tianyuan Healthcare (02373) with a "Buy" rating, highlighting its unique "Double Beauty + Double Health" ecological model, proven acquisition integration capabilities, and excellent operational efficiency, which are expected to drive sustained industry leadership and significant growth [1] Group 1: Company Overview - Established in 1993, the company has developed a comprehensive beauty and health management service system covering traditional beauty, medical beauty, and sub-health assessment and intervention [2] - The company owns four major brands: Meili Tianyuan, Beili Shi, Xiuker, and Yanyuan, and has strengthened its industry position through acquisitions of Nairui'er and Siyuanli, forming a synergistic ecological closed loop [2] Group 2: Financial Performance - The company demonstrates strong growth resilience, with revenue increasing from 1.503 billion in 2020 to 2.572 billion in 2024, representing a compound annual growth rate (CAGR) of 11.3% [3] - In the first half of 2025, revenue accelerated to 1.459 billion, a year-on-year increase of 28.2% [3] - Net profit attributable to shareholders rose from 151 million in 2020 to 228 million in 2024, with a year-on-year growth of 34.9% in the first half of 2025, reaching 156 million [3] - Gross margin improved to 49.33% in the first half of 2025, while net margin optimized to 10.67%, reflecting effective cost control and a higher proportion of high-margin business [3] - The company commits to a dividend payout ratio of no less than 50% of net profit attributable to shareholders over the next three years, indicating strong dividend levels [3] Group 3: Industry Outlook - The traditional beauty, light medical beauty, and sub-health sectors are expected to see long-term growth, with market sizes projected to reach 640.2 billion, 415.7 billion, and 29 billion respectively by 2030 [4] - As young consumers increasingly prioritize standardized services and stable experiences, the competitive landscape is expected to consolidate further, benefiting leading companies [4] Group 4: Business Synergy and Growth Strategy - The company's core business model exhibits significant synergy, utilizing its extensive and trusted beauty services as a front-end traffic source to efficiently convert to higher-priced medical beauty and sub-health services, with cross-business conversion rate reaching 28.7% in 2024 [5] - The company employs a strategy of "directly operated stores as benchmarks, franchising for coverage," leading to rapid expansion of its store network, totaling 554 by the end of 2024 [5] - The company has a mature target selection system and post-acquisition digital integration capabilities, as evidenced by the significant improvement in net profit margin following the acquisition of Nairui'er, validating its strong integration and empowerment capabilities [5]

Macro Strategy - The report discusses the "K-shaped differentiation" in China's consumption market, highlighting the split between high-end quality consumption and high cost-performance consumption driven by changes in income structure and generational shifts [6][8] - The K-shaped differentiation reflects a shift in consumer behavior, where emotional value is increasingly prioritized alongside practical value, leading to diverse consumption choices [6][8] - Retailers are adapting to this differentiation by adjusting their brand strategies and product offerings to cater to both ends of the consumer spectrum [6][8] Fixed Income - The report analyzes the current state of urban investment bonds in Fujian Province, indicating a high-pressure regulatory environment aimed at consolidating debt reduction achievements [2][12] - Fujian's economic performance is solid, with a GDP of 57,761 billion yuan and a growth rate of 5.50% in 2024, alongside a strong fiscal position with a public budget revenue of 3,615.29 billion yuan [2][12] - The report suggests a strategy of "regional digging → duration selection → rating down" for investment in urban investment bonds, emphasizing the importance of extending durations and focusing on platforms with strong debt repayment capabilities [2][12] Industry Analysis - The report highlights the growth potential of Meili Tianyuan Medical Health (02373.HK), which has established a comprehensive ecosystem in beauty and health management, showing strong revenue growth and profitability [4][13] - The company is expected to achieve net profits of 3.1 billion, 4.1 billion, and 5.2 billion yuan from 2025 to 2027, with corresponding growth rates of 36.67%, 31.79%, and 25.86% [4][13] - MINIMAX-WP (00100.HK) is positioned as a benchmark for AI export from China, with projected revenues of 0.81 billion, 1.95 billion, and 3.99 billion USD from 2025 to 2027, reflecting a compound growth rate exceeding 130% [5][15]